Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF ...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...

Pliant Therapeutics halted its Phase 2b trial for bexotegrast in IPF, raising concerns about future prospects. Needham downgraded Pliant to Hold from Buy, citing a lack of near-term catalysts and ...

Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical study of bexotegrast in patients with idiopathic pulmonary fibrosis, or ...

Pliant plans to assess the full trial data and may explore lower doses in future Phase 2b studies. Pelosi’s latest AI pick skyrocketed 169% in just one month. Click here to discover the next ...

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...